Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 1, 2008, Pages 49-54

  Alfieri, Anna B ^a   Briceno, Luis ^b   Fragasso, Gabriele ^c   Spoladore, Roberto ^c   Palloshi, Altin ^c   Bassanelli, Giorgio ^c   Montano, Chiara ^c   Arioli, Francesco ^c   Cuko, Amarild ^c   Ruotolo, Giacomo ^c   Margonato, Alberto ^c  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b INSTITUTO DE BIOMEDICINA   (Venezuela)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Carvedilol; Endothelial function; Heart failure; Inflammation

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; INTERLEUKIN 10; INTERLEUKIN 18; N(G),N(G) DIMETHYLARGININE; TORASEMIDE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CYTOKINE; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; PROPANOLAMINE DERIVATIVE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; BLOOD; DRUG ADMINISTRATION; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; ARGININE; CARBAZOLES; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-18; MALE; PROPANOLAMINES; PROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 55949108230     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31817e0edd     Document Type: Article

References (28)

1. Seta Y, Shan K, Bozkurt B, et al. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 1996;2:243-249.
2. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988-998.
3. Chong AY, Freestone B, Patel J, et al. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol. 2006;97:671-675.
4. Tatli E, Kurum T. A controlled study of the effects of carvedilol on clinical events left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Can J Cardiol. 2005;21:344-348.
5. Matsumura T, Tsushima K, Ohtaki E, et al. Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy. J Cardiol. 2002;39:253-257.
6. Tepliakov AT, Dibirov MM, Bolotskaia LA, et al. Effect of carvedilol on blood levels of cytokines and symptoms of heart failure in patients with postinfarction cardiac dysfunction. Kardiologia. 2004;44:50-57.
7. Rössig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cells apoptosis: protective role of carvedilol. J Am Coll Cardiol. 2000;36:2081-2089.
8. Mallat Z, Heymes C, Corbaz A, Logeart D, Alouani S, Cohen-Solal A, Seidler T, Hsenfuss G, Chvatchko Y, Shah AM, Tedqui A. Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure. FASEB J. 2004;18:1752-1754.
9. White M, Ducharme A, Ibrahim R, et al. Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clin Sci (Lond). 2006; 110:483-489.
10. Dinarello CA. Novel targets for interleukin 18 binding protein. Ann Rheum Dis. 2001;60:18-24.
11. Kaur K, Sharma AK, Singal PK. Significance of changes in TNF-alpha and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;291:106-113.
12. Tziakas DN, Chalikias GK, Kaski JC, et al. Inflammatory and antiinflammatory variable clusters and risk prediction in acute coronary syndrome patients: A factor analysis approach. Atherosclerosis. 2007;193: 196-203.
13. Chalikias GK, Tziakas DN, Kaski JC, et al. Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome. Int J Cardiol. 2007;117:333-339.
14. Lee DS, Vasan RS. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol. 2005;20:201-210.
15. Katz SD, Hryniewicz K, Hriljac I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005; 111:310-314.
16. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000;20:2032-2037.
17. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005;97: e53-59.
18. Szuba A, Podgorski M. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor - evidence from epidemiological and prospective clinical trials. Pharmacol Rep. 2006;58:16-20.
19. Swedberg K, Cleland J, Dargie H, et al; Grupo de Trabajo de Diagnostico y Tratamiento de la Insuficiencia Cardiaca Cronica de la Sociedad Europea de Cardiologia; Comite de la ESC para la elaboraciòn de las Guias de Practica Clinica. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-1140.
20. Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:42-50.
21. Beltowski J, Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacological Rep. 2006;58:159-178.
22. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996;94:2807-2816.
23. Reiffel JA. Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era. J Cardiovasc Pharmacol Ther. 2005; 10:S45-S58.
24. Yang SP, Ho LJ, Cheng SM, et al. Carvedilol differentially regulates cytokine production from activated human peripheral blood mononuclear cells. Cardiovasc Drugs Ther. 2004;18:183-188.
25. Zhao J, Yang Y, You S, et al. Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Int J Cardiol. 2007;115:334-341.
26. Saijonmaa O, Nyman T, Fyhrquist F. Carvedilol inhibits basal and stimulated ACE production in human endothelial cells. Cardiovasc Pharmacol. 2004;43:616-621.
27. DeGeorge BR Jr, Koch WJ. Beta blocker specificity: a building block toward personalized medicine. J Clin Invest. 2007;117:86-89.
28. Cintron G, Johnson G, Francis G, et al. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI17-123.